# A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

> **NCT05085444** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 9 (estimated)

## Conditions studied

- Scleroderma
- Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** Assigned Interventions CD19/BCMA CAR T-cells

## Key facts

- **NCT ID:** NCT05085444
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-08
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085444, "A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05085444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*